Singapore, July 8 -- Inocras Inc., a global leader in whole-genome sequencing (WGS) and bioinformatics, has announced the signing of a Memorandum of Understanding (MoU) with ChiMei Medical Center (CMMC), a premier medical institution in Taiwan, and Trivator Biomedical, a biomedical advisory firm in Taiwan.

This expansion agreement aims to introduce Inocras's MRDVision tumour-informed minimal residual disease (MRD) test, utilising circulating tumour DNA (ctDNA) blood samples, and CancerVision, its artificial intelligence (AI)-powered bioinformatics cloud solution, to support WGS at CMMC, advancing Taiwan's precision oncology landscape.

This initiative brings together CMMC's in-house WGS laboratory infrastructure with Inocras's advanced b...